CEO Michelle Berrey said Chimerix Inc.'s solid financial position of $378 million in cash at the end of the third quarter will let the firm "make the best strategic decisions around the brincidofovir programs" after the oral nucleotide analog's top-line phase III failure in the trial called SUPPRESS, which tested the compound against cytomegalovirus in hematopoietic cell transplant patients. Read More
While several patent questions continue to hang over the life sciences sector as 2015 gives way to the new year, the most immediate one concerns the lingering impact from last week's disabling power disruption at the U.S. Patent and Trademark Office's (USPTO) headquarters in Alexandria, Va. Read More
In a way, it was a back to the base-ics year for scientific advances. Two of the biggest science stories of the year are about the fundamental building block of biotechnology, namely, DNA – how to repair it in one case and how to edit it in another. Read More
DUBLIN – Will tempol, a tool compound long used for its intracellular antioxidant effects, prove to be of clinical benefit to patients with cerebral cavernous malformation (CCM)? Read More
As a small country, New Zealand has always needed to punch above its weight to be noticed, whether in sports, entertainment or science. With its rugby team the All Blacks recent winners of the Rugby World Cup, and the global success of the "Lord of the Rings" and "The Hobbit" film trilogies, there's another area where New Zealand is overachieving considering its population of just 4 million: cancer immunotherapy. Read More
Northwest Biotherapeutics Inc., of Bethesda, Md., said it the closed its previously announced registered direct placement with health care-focused institutional investors, for gross proceeds of $12.6 million. Read More
Epizyme Inc., of Cambridge, Mass., said the FDA's division of hematology products has accepted the company's investigational new drug application for tazemetostat for the treatment of adults with diffuse large B-cell lymphoma (DLBCL). Read More
Rich Pharmaceuticals Inc., of Beverly Hills, Calif., said the company has received FDA approval to begin its phase I/II trial for the treatment of acute myelocytic leukemia and myelodysplastic syndrome patients. Read More
